Gamco Investors INC. ET AL bought a new stake in NxStage Medical, Inc. (NASDAQ:NXTM) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 22,153 shares of the medical device company’s stock, valued at approximately $611,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. State of Wisconsin Investment Board acquired a new position in shares of NxStage Medical in the 3rd quarter valued at approximately $13,403,000. ARP Americas LLC acquired a new position in shares of NxStage Medical in the 3rd quarter valued at approximately $11,219,000. Athos Capital Ltd acquired a new position in shares of NxStage Medical in the 3rd quarter valued at approximately $557,000. Aperio Group LLC raised its position in shares of NxStage Medical by 36.8% in the 3rd quarter. Aperio Group LLC now owns 11,123 shares of the medical device company’s stock valued at $307,000 after purchasing an additional 2,990 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC acquired a new position in shares of NxStage Medical in the 3rd quarter valued at approximately $373,000. 92.31% of the stock is currently owned by institutional investors.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/16/gamco-investors-inc-et-al-invests-611000-in-nxstage-medical-inc-nxtm.html.

Shares of NxStage Medical, Inc. (NXTM) opened at $25.82 on Thursday. NxStage Medical, Inc. has a twelve month low of $20.45 and a twelve month high of $30.80.

In related news, SVP Matthew W. Towse sold 4,300 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $27.27, for a total transaction of $117,261.00. Following the completion of the transaction, the senior vice president now directly owns 28,721 shares in the company, valued at approximately $783,221.67. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $27.95, for a total value of $27,950.00. Following the transaction, the president now owns 73,903 shares of the company’s stock, valued at $2,065,588.85. The disclosure for this sale can be found here. Insiders sold a total of 17,600 shares of company stock valued at $484,722 over the last quarter. Company insiders own 4.70% of the company’s stock.

NXTM has been the subject of a number of research analyst reports. Jefferies Group LLC downgraded NxStage Medical from a “buy” rating to a “hold” rating and lowered their price target for the company from $33.00 to $30.00 in a report on Tuesday, August 8th. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, August 10th. BTIG Research downgraded NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. Northland Securities reiterated a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a report on Monday, August 7th. Finally, Canaccord Genuity downgraded NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target for the company. in a report on Monday, August 7th. Two research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company. NxStage Medical presently has an average rating of “Hold” and a consensus target price of $30.25.

NxStage Medical Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.